- Human（1）
No data
- His Tag & Avi Tag（1）
No data
- HEK293（1）
No data
- Biotin-labeled（1）
No data
- RUO（1）
No data
- No（1）
No data
- 25ug/$360.00
- 200ug/$1565.00
No data
| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Semaphorin 7A | Avitag SEA-H82E7 | Biotinylated Human Semaphorin 7A / SEMA7A Protein, His,Avitag™ |  Human | HEK293 |  | SDS-PAGE | $360.00 25ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Donaperminogene seltoplasmid (ViroMed) | VM202-Stent; VM202-PAD; pCK-HGF-X7; VM202-DPN; VM-202CAD; VM-202ALS; VM202-RY; VM-202; NL-003; HGF-X7 | Phase 3 Clinical | Viromed | Myocardial Ischemia; Diabetic Foot; Charcot-Marie-Tooth Disease; Intermittent Claudication; Myocardial Infarction; Arterial Occlusive Diseases; Peripheral Vascular Diseases; Diabetic Neuropathies; Ischemia; Diabetic peripheral neuropathy; Ulcer; Amyotrophic Lateral Sclerosis; Peripheral Arterial Disease | 詳細 |
| Fosgonimeton | ATH-1017; NDX-1017 | Phase 3 Clinical | M3 Biotechnology | Alzheimer Disease; Lewy Body Disease | 詳細 |
| Ficlatuzumab | AV-299; SCH-900105 | Phase 3 Clinical | Aveo | Multiple Myeloma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Oropharyngeal Neoplasms; Cholangiocarcinoma; Respiratory Tract Neoplasms; Solid tumours; Colonic Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Head and Neck Neoplasms; Liver Neoplasms | 詳細 |
| MP-0250 | MP-0250 | Phase 2 Clinical | Molecular Partners Ag | Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung | 詳細 |
| YYB-101 | NOV-1105; YYB-101 | Phase 2 Clinical | Yooyoung | Solid tumours; Colorectal Neoplasms | 詳細 |
| ATH-1020 | ATH-1020 | Phase 1 Clinical | Athira Pharma Inc | 詳細 | |
| Microbiome-optimized autologous stem cell therapy (Biotech Holdings) | Clinical | Biotech Holdings | Peripheral Vascular Diseases | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beperminogene perplasmid | DS-992; AMG-0001; TREAT-HGF; AMG-0001-01 | Approved | Anges Mg, Osaka University | Collategene | Japan | Ischemia; Peripheral Arterial Disease | null, Anges Inc | 2019-03-01 | Arterial Occlusive Diseases; Peripheral Vascular Diseases; Atherosclerosis; Vascular Diseases; Foot Ulcer; Ischemia; Ulcer; Peripheral Arterial Disease | 詳細 |
